2008
DOI: 10.1016/s1359-6349(08)72031-7
|View full text |Cite
|
Sign up to set email alerts
|

99 POSTER Models for response to the MEK inhibitor GSK1120212 confirm RAS and BRAF mutations as predictive biomarkers and suggest other, unexpected tumor types for clinical evaluation

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles